The Need For 100,000 Psychedelic Facilitators Is Real
LA Weekly, 03 August, 2022
The experts are pretty sure it’s going to take 100,000 psychedelic facilitators for the new industry to provide treatment to the masses.
Canadian patients fighting for psilocybin access sue federal government
National Post, 02 August, 2022
‘This is the landmark case that is going to legalize psychedelics in Canada’
Restrictions on Psilocybin ‘Magic Mushrooms’ Are Easing as Research Ramps Up
Scientific American, 01 August, 2022
Here’s how the psychedelic substance’s legal status has been shifting.
Biden administration plans for legal psychedelic therapies within two years
The Intercept, 27 July, 2022
A letter from the Health and Human Services Department discloses the anticipated FDA approval of MDMA and psilocybin treatments.
Microdosing: Scientists tackle psychedelic trend becoming ‘creative enhancer of choice’
The Age, 23 July, 2022
Microdosing is a different way of consuming psychedelic medicines, which involves regularly taking small amounts of a psychedelic.
Brains, genes and chemical imbalances – how explanations of mental illness affect stigma
The Conversation, 20 July, 2022
For three decades, people have been deluged with information suggesting that depression is caused by a “chemical imbalance” in the brain – namely an imbalance of a brain chemical called serotonin. However, our latest research review shows that the evidence does not support it.
Psychedelics for mental health treatment
ABC Nightlife, 11 July, 2022
Writer Michael Pollan discusses how psychedelics are being used now and into the future, to successfully treat people with a range of disorders, addictions and mental illnesses.
Can microdosing psychedelics improve your mental health? Here's what the science says
ABC News, 03 July, 2022
Early results from trials on the therapeutic potential of large doses (macrodosing) of psychedelics have been promising.
Psychedelics Give a Glimpse of Enlightenment
Psychology Today, 03 July, 2022
Our brains may be filters that are inhibiting us from experiencing reality.
Mark Turner MLA speaks at the Legislative Assembly of the Northern Territory
Mark Turner MLA: Member for Blain , 28 June, 2022
Mark Turner MLA advocates for access to psychedelic-assisted psychotherapies at the Legislative Assembly of the Northern Territory.
ACT government agrees to decriminalise small amounts of illicit drugs, such as ice, heroin and cocaine
ABC News, 09 June, 2022
The ACT is set to become the first Australian jurisdiction to decriminalise small amounts of commonly used illicit drugs, such as ice, heroin, cocaine and speed.
‘As legal as garlic’: High times in Thailand as marijuana is decriminalised
The Sydney Morning Herald, 08 June, 2022
Thailand will on Thursday become the first country in Asia to effectively legalise marijuana in a landmark move its government hopes will supercharge its wellness and tourism industries and generate as much as 10 billion baht ($400 million) per year.
How psychedelic drugs might treat depression
BBC, 07 June, 2022
Hallucinogenic mushrooms have shown promise for their medical benefits, but we are only now beginning to understand how they might help to treat depression.
New Study To Evaluate Psilocybin’s Therapeutic Potential On Autistic Adults
Neuroscience News, 04 June, 2022
A new study will explore how psilocybin affects different networks and serotonin function in the brains of autistic adults.
Psychedelic retreats target stressed-out corporate executives
Australian Financial Review, 02 June, 2022
New businesses are focusing on jurisdictions where drugs such as psilocybin and ketamine are legal, betting they’ll be able to expand when more places decriminalise popular substances.
‘We spark curiosity’: how the psychedelics industry is taking on Davos
The Guardian, 01 June, 2022
The Psychedelic House of Davos, a satellite event happening in conjunction with the World Economic Forum, was a ‘genius strategy’ to build credibility, say experts.
Israeli company reveals nasal spray of psychedelic mushrooms
Al-Monitor, 09 May, 2022
Madrigal Mental Care says the spray treats post-traumatic stress disorder, anxiety and other mental challenges. Some experts believe magic mushrooms have health benefits, though they come with risks.
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
Globe News Wire, 03 May, 2022
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans.
Trending Clinical Topic: Psychedelics
MedScape, 22 April, 2022
A new study examined changes in specific neurotransmitter systems and brain regions that may be responsible for various experiences associated with a psychedelic “trip”.
Australian researchers trialling magic mushroom active ingredient as antidepressant
9 News, 27 April, 2022
Sydney researchers are testing psilocybin as an alternative to antidepressants.
GoDaddy Billionaire Bob Parsons Believes Psychedelics Can Heal Trauma—And He’s Putting His Money (And Brain) On The Line
Forbes, 17 April, 2022
The Marine infantryman still suffers from PTSD from his tour in Vietnam but credits LSD and MDMA with helping him “come home.” Now he’s on a mission to help other veterans.
‘Magic mushrooms’ for PTSD therapy? Vets help sway conservatives
LA Times, 16 April, 2022
Matthew Butler spent 27 years in the Army, but it took a day in jail to convince him that his post-traumatic stress disorder was out of control.
Psychedelic frees up depressed brain, study shows
BBC News, 12 April, 2022
Psilocybin appears to free up the brains of people with severe depression in a way that other antidepressants do not, a study has found.
What the science says about microdosing
Australian Financial Review, 08 April, 2022
Scientists have insight into what happens when someone takes enough psychedelics to experience hallucinogenic effects. But little research has been conducted on the effects of small doses.
6 terminally ill cancer patients in Canada received doses of the psychoactive substance found in 'magic' mushrooms after authorities eased rules
Business Insider, 07 April, 2022
Six terminally ill cancer patients in Canada received the country’s first legally produced psilocybin under new rules about access to the substance.
Psychedelics may ease cancer patients’ depression, anxiety
Washington Post, 02 April, 2022
Evidence indicates that psychedelics could reduce the end-of-life anxiety that many cancer patients experience.
LSD, a future anti-anxiety pill?
McGill University Health Centre, 18 March, 2022
A study conducted by Gabriella Gobbi, MD, Professor and Head of the Neurobiological Psychiatry Unit in the Department of Psychiatry, and her team demonstrates for the first time that regular administration of low doses of LSD (lysergic acid diethylamide) reduces anxiety symptoms through neurobiological mechanisms that are similar to those of selective serotonin reuptake inhibitors (SSRIs).
Johns Hopkins, Yale, and NYU are teaming up to tackle a key bottleneck that will arise as psychedelics come to market
Business Insider, 11 March, 2022
As psychedelics treatments move closer to regulatory approval, there’s an issue looming in the industry: the lack of trained professionals who can handle such powerful compounds.
MDMA-assisted psychotherapy for PTSD could save the health care system millions of dollars, study suggests
PsyPost, 11 March, 2022
New research provides evidence that MDMA-assisted psychotherapy can improve and extend lives of patients with chronic and severe post-traumatic stress disorder while also reducing healthcare costs.
Oklahoma House Passes Psilocybin Decriminalization Bill
Psychedelics Spotlight, 09 March, 2022
On Monday, the state’s Republican-controlled House of Representatives voted overwhelmingly, 62-30, to pass House Bill 3414, introduced by Rep. Daniel Pae (R).
4 Signs the Psychedelics Movement Is Unstoppable
Psychedelics Spotlight, 28 February, 2022
Dr. Nora Volkow, the Director of the National Institute on Drug Abuse, said earlier this year that the psychedelics “train has left the station,” and here are four big reasons to agree wholeheartedly.
Psilocybin Treatment for Major Depression Effective for up to a Year for Most Patients
Neuroscience News, 15 February, 2022
The antidepressant effect of psilocybin-assisted therapy, in combination with psychotherapy, appears to provide up to a year of symptom relief for some patients with major depressive disorder.
Two doses of psilocybin may ease depression symptoms for up to 12 months
News Medical, 15 February, 2022
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for some patients.
Colorado General Assembly, 10 February, 2022
Concerning establishing a policy review panel to study plant-based medicines to support mental health.
Psychedelics and the Future of Psychiatry
Psychiatric Times, 09 February, 2022
Over the past several years, we have witnessed a psychedelic renaissance, and a growing body of evidence suggests that several psychedelic compounds hold strong therapeutic potential for a wide array of mental health conditions.
Sensible policy on psychedelic drugs is growing more common
The Economist, 29 January, 2022
They show tremendous potential in treating certain mental health disorders.
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
VICE, 25 January, 2022
Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.
Ketamine for the treatment of alcoholism
Blossom Analysis, 24 January, 2022
Psychedelics are poised to be both viable and effective treatment options for many people living with mental disorders whom conventional treatments have failed. One of these disorders is substance use disorder (SUD), commonly known as addiction.
Psychedelics Offer New Route to Recovery from Eating Disorders
Neo.Life, 01 February, 2022
Psilocybin, MDMA, and ketamine can lead to a new sense of self and a release from rigid rules for people with anorexia, bulimia, and binge-eating disorder.
How 2021 became the year of psychedelics – and why 2022 is set to be even bigger
Canex, 20 January, 2022
It’s no secret that psychedelics are on the comeback trail, with a record number of trials and total investment in the hundreds of millions of dollars in 2021 alone.
Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest
Psychedelic Stock Watch, 10 January, 2022
In 2020, Health Canada began tentative steps to open up legal access to psychedelics-based therapies via “exemptions” granted through its Special Access Program (SAP).
Details from the program can be found here.
$14.8 million for innovative mental health clinical trials
Health.gov.au, 07 January, 2022
Seven clinical trials testing the use of potential breakthrough combination therapies to treat debilitating mental illnesses will receive a total of almost $15 million from the Australian Government’s Medical Research Future Fund (MRFF).
Therapists hail 'legalization' of medicinal psychedelic drugs
Calgary Herald, 07 January, 2022
Local therapists say Ottawa’s move allowing physicians to prescribe psychedelics is a “seismic shift” towards legalizing their medicinal use.
Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA
Benzinga, 05 January, 2022
In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.
Depression and Grief Wrecked a Man's Life—Until He Took Magic Mushroom Ingredient
Newsweek, 26 December, 2021
Five years after taking part in a clinical trial, Kirk Rutter, spoke to Newsweek about his experiences of the trial and its impact on his mental health.
New center to study psychedelics pops up at University of Texas at Austin
My Sanantonio, 20 December, 2021
The Dell Medical School at the University of Texas at Austin is launching the Center for Psychedelic Research and Therapy, the first-of-its-kind center dedicated to the research of drugs such as psilocybin mushrooms, ayahuasca, MDMA, and ibogaine.
New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin
VICE, 16 December, 2021
The non-profit Freedom to Operate used research from chemists and crystallographers to argue in a legal filing that Compass’ form of synthetic psilocybin is not a new invention.
Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms
The Growth Op, 13 December, 2021
Three Canadians struggling with mental health conditions have received exemptions to the Controlled Drugs and Substances Act from the federal Minister of Health Jean-Yves Duclos.
'This isn’t the 60s again’: psychedelics business takes off amid culture clash
The Guardian, 12 December, 2021
Experts fear if psychedelics fall exclusively into the hands of big pharma the industry will follow the same path as legal marijuana, making the rich richer.
Psychedelics for mental illness
ABC All in the Mind, 12 December, 2021
Major trials are bringing us a step closer to seeing psychedelic substances used in therapy practice for PTSD, anxiety and depression. On this episode of All in the Mind, we take a look at where the research is currently at with our Ambassadors Dr Rick Doblin and Professor David Nutt.
Psychedelics can change humanity for the better. It’s time to unlock their power
The Guardian, 26 November, 2021
Founder and Executive Director at MAPS and an Ambassador for Mind Medicine Australia, Dr Rick Doblin (USA) is at the heart of the psychedelic movement. In this article he shares some of his findings and progress.
Doctor takes bid to treat patient with MDMA to court, in first case of its kind in Australia
ABC News, 12 November, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.
New research brings psychedelic drugs a step closer to medical use
ABC: RN Breakfast with Fran Kelly, 10 November, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.
Monash presses go on psychedelics to tackle ‘mental health tsunami’
The Sydney Morning Herald, 10 November, 2021
Monash University has set its sights on capturing a slice of the multibillion dollar psychedelic medicines market, with the launch of a drug development centre for new psychiatric treatments, including those using MDMA and psilocybin.
Major announcement: COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Globenewswire, 09 November, 2021
Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support.
Will the magic of psychedelics transform psychiatry?
The Guardian, 07 November, 2021
Imagine a medicine that could help people process disturbing memories, sparking behavioural changes rather than merely burying and suppressing symptoms and trauma.
New research shows how psychedelic medicines can help people with PTSD
Today.com, 05 November, 2021
TODAY’s Savannah Guthrie spoke to two patients whose lives have been changed by the therapy.
World-first trial of psilocybin therapy for anxiety disorders to begin in Australia
Happymag, 01 November, 2021
Incannex Healthcare, in partnership with Monash University, has obtained ethics approval to begin the first-ever clinical trial investigating the effects of psilocybin assisted psychotherapy to treat generalised anxiety disorder (GAD).
Johns Hopkins Receives $4M From NIH To Study Psilocybin As Tool To Quit Smoking
Ganjapreneur, 22 October, 2021
Baltimore’s Johns Hopkins Medicine announced that the National Institutes of Health will provide nearly $4 million to help researchers study how psilocybin can affect tobacco addiction.
DEA Wants Way More Cannabis & Psychedelics for Research In 2022
Ganjapreneur, 18 October, 2021
The DEA has proposed massively increasing the production of research-grade cannabis and psychedelics like LSD, psilocybin, and MDMA next year.
Psychedelic research renaissance: The urgent quest for new mental health medicines
Lens Monash, 15 October, 2021
“There’s been a resurgence in research and interest in psychedelic medicine over the past two decades, and particularly so over the past five years,” says Dr Liknaitzky.
Could mushrooms, molly and acid be the new wave of mental health care?
NBC News, 13 October, 2021
Doctors are looking into psychedelics to possibly reduce anxiety and depression. NBC News’ Maya Eaglin reports on the new wave of mental health care.
National anxiety crisis worsens
The Australian, 03 October, 2021
Australians are reporting depression, anxiety and stress at higher rates than the same time last year, with four in five experiencing poor mental health, and children and young people the most seriously affected, as pandemic uncertainty and lockdowns continue to take a toll.
Psychedelics might reduce internalized shame and complex trauma symptoms in those with a history of childhood abuse
Psypost.org, 30 September, 2021
The use of psychedelic medicines is associated with lower levels of complex posttraumatic stress symptoms and internalized shame in adults who suffered maltreatment in childhood, according to new research published in the journal Chronic Stress.
Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac
Newsweek, 22 September, 2021
Psilocybin could be the biggest advance since Prozac.
Small pharma successfully completes phase 1 clinical trial of DMT in combination with supportive psychotherapy
Smallpharma.co.uk, 21 September, 2021
Small Pharma’s DMT-assisted therapy (SPL026) demonstrated to be well-tolerated and safe in psychedelic naïve volunteers.
Medicinal cannabis company Little Green Pharma gets green light for psychedelic drug production
ABC News, 10 September, 2021
A WA-based medicinal cannabis company has been given regulatory approval to produce psilocybin, a hallucinogenic substance found in magic mushrooms, to supply for medical research.
The worldview-changing drugs poised to go mainstream
BBC, 07 September, 2021
Our Ambassador Dr Rick Doblin (USA) is featured in this article by the BBC: The worldview-changing drugs poised to go mainstream.
Suicide line records highest number of calls in history
The Australian, 20 August, 2021
Australia’s biggest suicide support line has recorded the most calls for help it has ever received in one day, amid concerns about long-term mental health consequences of Covid-19 restrictions.
Read the article here or the PDF attached.